| 000 | 01685 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517110742.0 | ||
| 264 | 0 | _c20170403 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a2296-5262 | ||
| 024 | 7 |
_a10.1159/000447372 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Fengxia | |
| 245 | 0 | 0 |
_aSafety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. _h[electronic resource] |
| 260 |
_bOncology research and treatment _c2016 |
||
| 300 |
_a453-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Meta-Analysis; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCancer Pain _xepidemiology |
| 650 | 0 | 4 | _aCausality |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aDenosumab _xadministration & dosage |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPatient Safety |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xstatistics & numerical data |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aPu, Feifei | |
| 773 | 0 |
_tOncology research and treatment _gvol. 39 _gno. 7-8 _gp. 453-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000447372 _zAvailable from publisher's website |
| 999 |
_c26293442 _d26293442 |
||